RNS Number : 1442O
IXICO plc
27 January 2023
 

 

27 January 2023

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

 

 

RESOLUTION

VOTES
FOR

%

VOTES
AGAINST

%

VOTES
TOTAL

% ISC VOTED

VOTES
WITHHELD

1

Reports and Accounts

 

26,812,002

99.96%

11,472

0.04%

26,823,474

55.48

9,231

2a

Re-election of Giulio Cerroni

 

26,821,033

99.96%

11,372

0.04%

26,832,405

55.49

300

2b

Election of Kate Rogers

26,675,515

99.95%

12,670

0.05%

26,688,185

55.20

144,520

3

Re-appointment of Auditors

 

26,808,776

99.94%

16,198

0.06%

26,824,974

55.48

7,731

4

Allotment of Securities

 

26,812,002

99.93%

19,681

0.07%

26,831,683

55.49

1,022

5

* Disapply Pre-Emption Provisions

26,674,807

99.92%

22,559

0.08%

26,697,366

55.22

135,339

* Special Resolution

Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation

of the proportion of the votes 'for' and 'against' a resolution.    

 

For further information please contact:

 

IXICO plc

+44 (0)20 3763 7499

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 


 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Tamar Cranford-Smith (Sales)




About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.  

 

IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

 

 

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGNKOBPBBKDCDB